# Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

> **NCT04925986** · PHASE2 · TERMINATED · sponsor: **Sarah Goldberg** · enrollment: 9 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Lung Diseases
- Lung Neoplasms
- Metastatic Lung Non-Small Cell Carcinoma
- Stage IV Lung Non-Small Cell Cancer AJCC v7
- PD-L1 Gene Mutation
- Advanced Treatment-Naïve PD-L1
- Sitravatinib
- Pembrolizumab

## Interventions

- **DRUG:** Sitravatinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04925986
- **Lead sponsor:** Sarah Goldberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-10
- **Primary completion:** 2023-06-22
- **Final completion:** 2023-10-30
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Sponsor decision based on data from other clinical trials
- **Last updated:** 2025-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04925986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04925986, "Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04925986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*